A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

Medicine & Life Sciences

1. Double-Blind Method 100%
2. Cystic Fibrosis 99%
3. Mutation 85%
4. Safety 29%
5. Therapeutics 16%